An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers

Purpose The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied th...

Full description

Saved in:
Bibliographic Details
Published inMolecular imaging and biology Vol. 22; no. 6; pp. 1553 - 1561
Main Authors Wei, Junnian, Wang, Yung-hua, Lee, Chia Yin, Truillet, Charles, Oh, David Y., Xu, Yichen, Ruggero, Davide, Flavell, Robert R., VanBrocklin, Henry F., Seo, Youngho, Craik, Charles S., Fong, Lawrence, Wang, Cheng-I, Evans, Michael J.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.12.2020
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1536-1632
1860-2002
1860-2002
DOI10.1007/s11307-020-01527-3

Cover

Abstract Purpose The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4. Procedure A C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89 Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression. Results The tumor uptake of the 89 Zr-C4 minibody was higher than 89 Zr-C4 scFv and equivalent to previous data collected using 89 Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89 Zr-C4 scFv compared with 89 Zr-C4 minibody and 89 Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89 Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma. Conclusion In summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands.
AbstractList The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4.PURPOSEThe swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4.A C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression.PROCEDUREA C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression.The tumor uptake of the 89Zr-C4 minibody was higher than 89Zr-C4 scFv and equivalent to previous data collected using 89Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89Zr-C4 scFv compared with 89Zr-C4 minibody and 89Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma.RESULTSThe tumor uptake of the 89Zr-C4 minibody was higher than 89Zr-C4 scFv and equivalent to previous data collected using 89Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89Zr-C4 scFv compared with 89Zr-C4 minibody and 89Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma.In summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands.CONCLUSIONIn summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands.
Purpose The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4. Procedure A C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89 Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression. Results The tumor uptake of the 89 Zr-C4 minibody was higher than 89 Zr-C4 scFv and equivalent to previous data collected using 89 Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89 Zr-C4 scFv compared with 89 Zr-C4 minibody and 89 Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89 Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma. Conclusion In summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands.
PurposeThe swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to identify optimal platforms. To probe the significance of antibody format on image quality for PD-L1 imaging, we developed and studied the biodistribution of a library of antibodies based on the anti-PD-L1 IgG1 clone C4.ProcedureA C4 minibody and scFv were cloned, expressed, and characterized. The antibodies were functionalized with desferrioxamine and radiolabeled with Zr-89 to enable a rigorous comparison with prior data collected using 89Zr-labeled C4 IgG1. The biodistribution of the radiotracers was evaluated in C57Bl6/J or nu/nu mice bearing B16F10 or H1975 tumors, respectively, which are models that represent high and low tumor autonomous PD-L1 expression.ResultsThe tumor uptake of the 89Zr-C4 minibody was higher than 89Zr-C4 scFv and equivalent to previous data collected using 89Zr-C4 IgG1. However, the peak tumors to normal tissue ratios were generally higher for 89Zr-C4 scFv compared with 89Zr-C4 minibody and 89Zr-IgG1. Moreover, an exploratory study showed that the rapid clearance of 89Zr-C4 scFv enabled detection of endogenous PD-L1 on a genetically engineered and orthotopic model of hepatocellular carcinoma.ConclusionIn summary, these data support the use of low molecular weight constructs for PD-L1 imaging, especially for tumor types that manifest in abdominal organs that are obstructed by the clearance of high molecular weight radioligands.
Author Ruggero, Davide
Seo, Youngho
Fong, Lawrence
Wei, Junnian
Oh, David Y.
Craik, Charles S.
Flavell, Robert R.
Wang, Yung-hua
Wang, Cheng-I
Lee, Chia Yin
Truillet, Charles
Xu, Yichen
VanBrocklin, Henry F.
Evans, Michael J.
AuthorAffiliation 1 Department of Radiology and Biomedical Imaging, University of California San Francisco 505 Parnassus Ave, San Francisco CA 94143
5 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143
3 Imagerie Moleculaire In Vivo, INSERM, CEA, Univ. Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay France, 94100
7 Department of Pharmaceutical Chemistry, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143
6 Department of Urology, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143
2 Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR), 8A Biomedical Grove Immunos #03-06, Biopolis Singapore 138648
4 Department of Medicine, University of California San Francisco, 513 Parnassus Ave, San Francisco CA 94143
AuthorAffiliation_xml – name: 7 Department of Pharmaceutical Chemistry, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143
– name: 3 Imagerie Moleculaire In Vivo, INSERM, CEA, Univ. Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot, Orsay France, 94100
– name: 4 Department of Medicine, University of California San Francisco, 513 Parnassus Ave, San Francisco CA 94143
– name: 2 Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR), 8A Biomedical Grove Immunos #03-06, Biopolis Singapore 138648
– name: 6 Department of Urology, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143
– name: 5 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 505 Parnassus Ave, San Francisco CA 94143
– name: 1 Department of Radiology and Biomedical Imaging, University of California San Francisco 505 Parnassus Ave, San Francisco CA 94143
Author_xml – sequence: 1
  givenname: Junnian
  surname: Wei
  fullname: Wei, Junnian
  organization: Department of Radiology and Biomedical Imaging, University of California San Francisco
– sequence: 2
  givenname: Yung-hua
  surname: Wang
  fullname: Wang, Yung-hua
  organization: Department of Radiology and Biomedical Imaging, University of California San Francisco
– sequence: 3
  givenname: Chia Yin
  surname: Lee
  fullname: Lee, Chia Yin
  organization: Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR)
– sequence: 4
  givenname: Charles
  surname: Truillet
  fullname: Truillet, Charles
  organization: Imagerie Moleculaire In Vivo, INSERM, CEA, Univ. Paris Sud, CNRS, Universite Paris Saclay, CEA-Service Hospitalier Frederic Joliot
– sequence: 5
  givenname: David Y.
  surname: Oh
  fullname: Oh, David Y.
  organization: Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
– sequence: 6
  givenname: Yichen
  surname: Xu
  fullname: Xu, Yichen
  organization: Department of Urology, University of California San Francisco
– sequence: 7
  givenname: Davide
  surname: Ruggero
  fullname: Ruggero, Davide
  organization: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Department of Urology, University of California San Francisco
– sequence: 8
  givenname: Robert R.
  surname: Flavell
  fullname: Flavell, Robert R.
  organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
– sequence: 9
  givenname: Henry F.
  surname: VanBrocklin
  fullname: VanBrocklin, Henry F.
  organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
– sequence: 10
  givenname: Youngho
  surname: Seo
  fullname: Seo, Youngho
  organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
– sequence: 11
  givenname: Charles S.
  surname: Craik
  fullname: Craik, Charles S.
  organization: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Department of Pharmaceutical Chemistry, University of California San Francisco
– sequence: 12
  givenname: Lawrence
  surname: Fong
  fullname: Fong, Lawrence
  organization: Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
– sequence: 13
  givenname: Cheng-I
  surname: Wang
  fullname: Wang, Cheng-I
  organization: Singapore Immunology Network, Agency for Science, Technology and Research (ASTAR)
– sequence: 14
  givenname: Michael J.
  orcidid: 0000-0003-4947-1316
  surname: Evans
  fullname: Evans, Michael J.
  email: michael.evans@ucsf.edu
  organization: Department of Radiology and Biomedical Imaging, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Department of Pharmaceutical Chemistry, University of California San Francisco
BookMark eNqNUU1vEzEUXKEi-gF_gJMlLlwW_PzWa-eCFPUDKqWiKkUcLcfr3bhy1sHeJeTf4yWRKnqoOPnpeWY0b-a0OOpDb4viLdAPQKn4mACQipIyWlLgTJT4ojgBWdOSUcqO8syxLqFGdlycpvRAKQhg-Ko4RiYBAdhJ8Xvek3mv_S65REJLrlMwPuRF3g5uGZoduQpxrYdEvo1dZ1MeNLkL3pI2RHJjdRqj6ztye1EugGzdsCKLsCU3GWFGryP5YV23Gsjt5T25040LQ9TGxvS6eNlqn-ybw3tWfL-6vD__Ui6-fr4-ny9KU3EYSmioFlWll4i1NaLChiOjy-x-JmeWtUYgrRrKGEfZoBVWCs3RzgA5WGsAzwrc6479Ru-22nu1iW6t404BVVOOap-jyjmqvzkqzKxPe9ZmXK5tY2yfbT8yg3bq35_erVQXfilR17NaVlng_UEghp9jjk2tXTLWe93bMCbFKuQ8VwAyQ989gT6EMeYKJpRAIflMTo7YHmViSCna9v_OkE9Ixg16cGEy7fzz1ENuaTP1a-Ojq2dYfwAVMscn
CitedBy_id crossref_primary_10_3390_cells10113165
crossref_primary_10_3390_cells10113166
crossref_primary_10_2967_jnumed_124_268586
crossref_primary_10_1016_j_adro_2022_100936
crossref_primary_10_1021_acs_molpharmaceut_2c00497
crossref_primary_10_3390_biomedicines10020236
crossref_primary_10_1002_smtd_202400358
crossref_primary_10_1016_j_jpha_2022_09_001
crossref_primary_10_3390_jpm11121312
crossref_primary_10_3390_ijms222212314
crossref_primary_10_2967_jnumed_121_262967
crossref_primary_10_3390_ijms222212297
crossref_primary_10_3390_ijms222212330
Cites_doi 10.1021/acs.molpharmaceut.9b00010
10.1038/s41591-018-0321-2
10.1021/acs.bioconjchem.8b00632
10.1200/JCO.2012.42.4887
10.1158/1535-7163.MCT-14-0983
10.7150/thno.37924
10.2967/jnumed.116.177659
10.1038/s41568-019-0116-x
10.1038/s41467-018-07131-y
10.2967/jnumed.116.177493
10.1039/C9CC00445A
10.1038/s41591-018-0255-8
10.2967/jnumed.117.199596
10.1021/acs.molpharmaceut.8b00399
10.1021/acs.bioconjchem.7b00631
10.1016/j.ccell.2014.12.004
10.1186/s40425-019-0768-9
10.2967/jnumed.119.240895
ContentType Journal Article
Copyright World Molecular Imaging Society 2020
World Molecular Imaging Society 2020.
Copyright_xml – notice: World Molecular Imaging Society 2020
– notice: World Molecular Imaging Society 2020.
DBID AAYXX
CITATION
7QO
8FD
FR3
K9.
NAPCQ
P64
7X8
5PM
ADTOC
UNPAY
DOI 10.1007/s11307-020-01527-3
DatabaseName CrossRef
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1860-2002
EndPage 1561
ExternalDocumentID oai:pubmedcentral.nih.gov:7669684
PMC7669684
10_1007_s11307_020_01527_3
GrantInformation_xml – fundername: National Institute of Biomedical Imaging and Bioengineering
  grantid: R01EB025207
  funderid: http://dx.doi.org/10.13039/100000070
– fundername: American Cancer Society
  grantid: 130635-RSG-17-005-01-CCE
  funderid: http://dx.doi.org/10.13039/100000048
– fundername: Prostate Cancer Foundation
  grantid: N/A
  funderid: http://dx.doi.org/10.13039/100000892
– fundername: National Cancer Institute
  grantid: 130635-RSG-17-005-01-CCE; U01CA233100; U01CA244452; P41CA196276; R35CA242986; P30CA082103
  funderid: http://dx.doi.org/10.13039/100000054
GroupedDBID ---
--K
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
04C
06C
06D
0R~
0VY
123
1B1
1N0
203
29M
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3V.
4.4
406
408
409
40D
40E
53G
5VS
67Z
6NX
7RV
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAEDT
AAHNG
AAIAL
AAJBT
AAJKR
AALRI
AANXM
AANZL
AAQFI
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAXUO
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJCF
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABWVN
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIUM
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACRPL
ACSNA
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADMUD
ADNMO
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRDE
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBNVY
BDATZ
BENPR
BGLVJ
BGNMA
BHPHI
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIHBH
EIOEI
EJD
EMOBN
EN4
ESBYG
EX3
F5P
FDB
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HCIFZ
HF~
HG5
HG6
HLICF
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
L6V
LK8
LLZTM
M1P
M41
M4Y
M7P
M7S
MA-
N2Q
NAPCQ
NB0
NPVJJ
NQ-
NQJWS
NU0
O9-
O93
O9I
O9J
OAM
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PTHSS
Q2X
QOR
QOS
R89
R9I
RIG
RNS
ROL
RPX
RPZ
RRX
RSV
S16
S1Z
S27
S37
S3B
SAP
SDH
SEW
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TT1
TUC
TUS
U2A
U9L
UG4
UHS
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
YLTOR
Z45
Z7U
Z7X
Z82
Z83
Z87
ZMTXR
ZOVNA
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ACVFH
ADCNI
ADHKG
AEUPX
AEZWR
AFDZB
AFHIU
AFOHR
AFPUW
AGQPQ
AHPBZ
AHWEU
AIGII
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PUEGO
7QO
8FD
FR3
K9.
P64
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c451t-1d0a744ab336ec743d5320b131989e2fc7304d022538d3e7e87a53e91351eec13
IEDL.DBID U2A
ISSN 1536-1632
1860-2002
IngestDate Sun Oct 26 04:05:23 EDT 2025
Thu Aug 21 14:10:28 EDT 2025
Fri Sep 05 10:20:33 EDT 2025
Tue Oct 07 06:37:37 EDT 2025
Thu Apr 24 23:04:44 EDT 2025
Wed Oct 01 02:09:30 EDT 2025
Fri Feb 21 02:36:52 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Immune checkpoint inhibitor
Precision medicine
Immunotherapy
Predictive biomarker
Cancer
Language English
License Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c451t-1d0a744ab336ec743d5320b131989e2fc7304d022538d3e7e87a53e91351eec13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally.
ORCID 0000-0003-4947-1316
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/7669684
PMID 32813112
PQID 2473785983
PQPubID 55372
PageCount 9
ParticipantIDs unpaywall_primary_10_1007_s11307_020_01527_3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7669684
proquest_miscellaneous_2435531118
proquest_journals_2473785983
crossref_primary_10_1007_s11307_020_01527_3
crossref_citationtrail_10_1007_s11307_020_01527_3
springer_journals_10_1007_s11307_020_01527_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-12-01
PublicationDateYYYYMMDD 2020-12-01
PublicationDate_xml – month: 12
  year: 2020
  text: 2020-12-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: New York
PublicationTitle Molecular imaging and biology
PublicationTitleAbbrev Mol Imaging Biol
PublicationYear 2020
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Mayer, Natarajan, Gordon, Maute, McCracken, Ring, Weissman, Gambhir (CR19) 2017; 58
Bensch, van der Veen, Lub-de Hooge, Jorritsma-Smit, Boellaard, Kok, Oosting, Schröder, Hiltermann, van der Wekken, Groen, Kwee, Elias, Gietema, Bohorquez, de Crespigny, Williams, Mancao, Brouwers, Fine, de Vries (CR7) 2018; 24
Krekorian, Fruhwirth, Srinivas, Figdor, Heskamp, Witney, Aarntzen (CR5) 2019; 9
Wissler, Ehlerding, Lyu, Zhao, Zhang, Eshraghi, Buuh, McGuth, Guan, Engle, Bartlett, Voelz, Cai, Wang (CR17) 2019; 16
De Silva, Kumar, Lisok (CR15) 2018; 15
Donnelly, Smith, Morin, Lipovšek, Gokemeijer, Cohen, Lafont, Tran, Cole, Wright, Kim, Pena, Kukral, Dischino, Chow, Gan, Adelakun, Wang, Cao, Leung, Bonacorsi, Hayes (CR18) 2018; 59
Davis, Patel (CR6) 2019; 7
CR9
Schumacher, Kesmir, van Buuren (CR1) 2015; 27
Hu, Kuan, Hanyu, Masayuki, Xie, Zhang, Nagatsu, Kotaro, Suzuki, Hisashi, Zhang (CR16) 2019; 55
Knowles, Wu (CR10) 2012; 30
Xu, Poggio, Jin, Shi, Forester, Wang, Stumpf, Xue, Devericks, So, Nguyen, Griselin, Gordan, Umetsu, Reich, Worland, Asthana, Barna, Webster, Cunningham, Ruggero (CR13) 2019; 25
Patel, Kurzrock (CR2) 2015; 14
Havel, Chowell, Chan (CR3) 2019; 19
Niemeijer, Leung, Huisman, Bahce, Hoekstra, van Dongen, Boellaard, du, Hayes, Smith, Windhorst, Hendrikse, Poot, Vugts, Thunnissen, Morin, Lipovsek, Donnelly, Bonacorsi, Velasquez, de Gruijl, Smit, de Langen (CR8) 2018; 9
Moroz, Lee, Wang, Hsiao, Sevillano, Truillet, Craik, Fong, Wang, Evans (CR12) 2018; 29
Hu, Shively, Raubitschek (CR14) 1996; 56
Ehlerding, England, McNeel, Cai (CR4) 2016; 57
Truillet, Oh, Yeo, Lee, Huynh, Wei, Parker, Blakely, Sevillano, Wang, Shen, Olivas, Jami, Moroz, Jego, Jaumain, Fong, Craik, Chang, Bivona, Wang, Evans (CR11) 2018; 29
HL Wissler (1527_CR17) 2019; 16
F Bensch (1527_CR7) 2018; 24
DJ Donnelly (1527_CR18) 2018; 59
A Moroz (1527_CR12) 2018; 29
JJ Havel (1527_CR3) 2019; 19
RA De Silva (1527_CR15) 2018; 15
K Hu (1527_CR16) 2019; 55
EB Ehlerding (1527_CR4) 2016; 57
C Truillet (1527_CR11) 2018; 29
SP Patel (1527_CR2) 2015; 14
AA Davis (1527_CR6) 2019; 7
AT Mayer (1527_CR19) 2017; 58
TN Schumacher (1527_CR1) 2015; 27
Y Xu (1527_CR13) 2019; 25
AN Niemeijer (1527_CR8) 2018; 9
SM Knowles (1527_CR10) 2012; 30
M Krekorian (1527_CR5) 2019; 9
S Hu (1527_CR14) 1996; 56
1527_CR9
References_xml – volume: 16
  start-page: 2028
  year: 2019
  end-page: 2036
  ident: CR17
  article-title: Site-specific immuno-PET tracer to image PD-L1
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.9b00010
– volume: 25
  start-page: 301
  year: 2019
  end-page: 311
  ident: CR13
  article-title: Translation control of the immune checkpoint in cancer and its therapeutic targeting
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0321-2
– volume: 29
  start-page: 3476
  year: 2018
  end-page: 3482
  ident: CR12
  article-title: A preclinical assessment of (89)Zr-atezolizumab identifies a requirement for carrier added formulations not observed with (89)Zr-C4
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.8b00632
– volume: 30
  start-page: 3884
  year: 2012
  end-page: 3892
  ident: CR10
  article-title: Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.42.4887
– volume: 14
  start-page: 847
  year: 2015
  end-page: 856
  ident: CR2
  article-title: PD-L1 expression as a predictive biomarker in cancer immunotherapy
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-14-0983
– volume: 9
  start-page: 7924
  year: 2019
  end-page: 7947
  ident: CR5
  article-title: Imaging of T-cells and their responses during anti-cancer immunotherapy
  publication-title: Theranostics
  doi: 10.7150/thno.37924
– volume: 58
  start-page: 538
  year: 2017
  end-page: 546
  ident: CR19
  article-title: Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.177659
– volume: 19
  start-page: 133
  year: 2019
  end-page: 150
  ident: CR3
  article-title: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0116-x
– volume: 9
  start-page: 4664
  year: 2018
  ident: CR8
  article-title: Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-07131-y
– volume: 57
  start-page: 1487
  year: 2016
  end-page: 1492
  ident: CR4
  article-title: Molecular imaging of immunotherapy targets in cancer
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.177493
– volume: 55
  start-page: 4162
  year: 2019
  end-page: 4165
  ident: CR16
  article-title: Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation
  publication-title: Chem Commun (Camb)
  doi: 10.1039/C9CC00445A
– ident: CR9
– volume: 24
  start-page: 1852
  year: 2018
  end-page: 1858
  ident: CR7
  article-title: (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0255-8
– volume: 59
  start-page: 529
  year: 2018
  end-page: 535
  ident: CR18
  article-title: Synthesis and biologic evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.117.199596
– volume: 15
  start-page: 3946
  year: 2018
  end-page: 3952
  ident: CR15
  article-title: Peptide-based (68)Ga-PET radiotracer for imaging PD-L1 expression in cancer
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.8b00399
– volume: 29
  start-page: 96
  year: 2018
  end-page: 103
  ident: CR11
  article-title: Imaging PD-L1 expression with ImmunoPET
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.7b00631
– volume: 56
  start-page: 3055
  year: 1996
  end-page: 3061
  ident: CR14
  article-title: Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
  publication-title: Cancer Res
– volume: 27
  start-page: 12
  year: 2015
  end-page: 14
  ident: CR1
  article-title: Biomarkers in cancer immunotherapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.12.004
– volume: 7
  start-page: 278
  year: 2019
  ident: CR6
  article-title: The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0768-9
– ident: 1527_CR9
  doi: 10.2967/jnumed.119.240895
– volume: 27
  start-page: 12
  year: 2015
  ident: 1527_CR1
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.12.004
– volume: 29
  start-page: 96
  year: 2018
  ident: 1527_CR11
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.7b00631
– volume: 59
  start-page: 529
  year: 2018
  ident: 1527_CR18
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.117.199596
– volume: 58
  start-page: 538
  year: 2017
  ident: 1527_CR19
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.177659
– volume: 30
  start-page: 3884
  year: 2012
  ident: 1527_CR10
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.42.4887
– volume: 9
  start-page: 7924
  year: 2019
  ident: 1527_CR5
  publication-title: Theranostics
  doi: 10.7150/thno.37924
– volume: 24
  start-page: 1852
  year: 2018
  ident: 1527_CR7
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0255-8
– volume: 56
  start-page: 3055
  year: 1996
  ident: 1527_CR14
  publication-title: Cancer Res
– volume: 7
  start-page: 278
  year: 2019
  ident: 1527_CR6
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0768-9
– volume: 55
  start-page: 4162
  year: 2019
  ident: 1527_CR16
  publication-title: Chem Commun (Camb)
  doi: 10.1039/C9CC00445A
– volume: 29
  start-page: 3476
  year: 2018
  ident: 1527_CR12
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.8b00632
– volume: 9
  start-page: 4664
  year: 2018
  ident: 1527_CR8
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-07131-y
– volume: 25
  start-page: 301
  year: 2019
  ident: 1527_CR13
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0321-2
– volume: 16
  start-page: 2028
  year: 2019
  ident: 1527_CR17
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.9b00010
– volume: 19
  start-page: 133
  year: 2019
  ident: 1527_CR3
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0116-x
– volume: 14
  start-page: 847
  year: 2015
  ident: 1527_CR2
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-14-0983
– volume: 57
  start-page: 1487
  year: 2016
  ident: 1527_CR4
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.177493
– volume: 15
  start-page: 3946
  year: 2018
  ident: 1527_CR15
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.8b00399
SSID ssj0017123
Score 2.3416204
Snippet Purpose The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative...
PurposeThe swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies...
The swell of new and diverse radiotracers to predict or monitor tumor response to cancer immunotherapies invites the opportunity for comparative studies to...
SourceID unpaywall
pubmedcentral
proquest
crossref
springer
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1553
SubjectTerms Antibodies
Cancer
Cancer immunotherapy
Comparative studies
Deferoxamine
Genetic engineering
Hepatocellular carcinoma
Image quality
Imaging
Immune checkpoint inhibitors
Immunoglobulin G
Immunotherapy
Liver cancer
Low molecular weights
Medicine
Medicine & Public Health
Molecular weight
Organs
PD-L1 protein
Radioactive tracers
Radioisotopes
Radiology
Research Article
Tumors
Zirconium isotopes
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTuLjgc8hCgMZiTeWronz1ccKVg20TlVZxXiKHNuBisypaKIx_nrunI_SPUzs2Y4c5-58v_jufgfwzkWvE3sqcNQw0g6ektKJM5tFmI2CbJTJIKPi5OlpeLzwP58H5zvgtrUwNmlfpsuByS8GZvnD5lauLuRhmyd2GIXE5-Lfgd0wQPjdg93F6Wz8reZFDR3EFzbCGYdD0gCvKZSpy-VcokSkH6YhdXN1-LYz2iDM6_mRXZD0AdyrzEpcXYo8_8cPTR7BvN1BnX7yc1CV6UD-uUbueKstPoaHDSpl43roCexo8xTuTpu4-zP4PTaspS9hRcY-oUzzwj5iymVaqCs2seB3zb5U3ylktWaCzYtcMwTFbGovInFrbPbROXEZXf6yk-KSTdvmvOyrvaJls6MzNhdqWeAXkYhM92AxOTr7cOw0PRsc6Qdu6bhqKCLfFynnoZYITxR1nkhdTrlZ2ssknii-QuCAB63iOtJxJAKuR9QoUGvp8ufQM4XRL4CpOEyFDvxUeppIbETqhyoTnkbQQaw_fXBb4SWyITSnvhp5sqFiJoEnKPDECjzhfXjfPbOq6TxunL3f6kTSmPY68fyIR3EwinH4bTeMRkmRFmF0UdEchHEc3Ujch2hLl7pVidZ7ewRVwdJ7N9Lvw0GrdZvFb3rXg04z_2NrL283_RXc98hubB7PPvTKX5V-jWisTN809vcX0M4tPw
  priority: 102
  providerName: Unpaywall
Title An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers
URI https://link.springer.com/article/10.1007/s11307-020-01527-3
https://www.proquest.com/docview/2473785983
https://www.proquest.com/docview/2435531118
https://pubmed.ncbi.nlm.nih.gov/PMC7669684
https://www.ncbi.nlm.nih.gov/pmc/articles/7669684
UnpaywallVersion submittedVersion
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1860-2002
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017123
  issn: 1860-2002
  databaseCode: AFBBN
  dateStart: 20050101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1860-2002
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017123
  issn: 1860-2002
  databaseCode: AGYKE
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1860-2002
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017123
  issn: 1860-2002
  databaseCode: U2A
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgk_h4QHxqhTEZiTdmqY7tOH3MoGXAWlVjFdtT5NgOqxQlE2217b_fnZekFKEJnqLIH3FyPvsX393vCHnPYddJIqeY62vPYJW0LCmCF2ExUMWgsKrA4OTxJD6cya-n6rQJClu03u6tSTKs1OtgN46Ehvi708dcrEzcJ9sK6bxgFs-itLMdaB6SuoEqxwzQRtSEyvy9j83taI0x__SQ7Mykj8nDVXVhri9NWf62E42ekicNhKTprcyfkXu-ek4ejBsj-QtylVa05RqhdUG_gADKOjSplvO8dtd0FJDqgn5f_UT70oIaelyXngKCpeNwagijoNNP7IhTPKmlR_UlHbeZdOmPcJ5Kp8MTemzcvIbBW4CRL8lsNDz5eMiaBAvMSsWXjLu-0VKaXIjYW8ASDtNE5FygI5WPCgvqLx3s8rAqOuG1T7RRwg8wq5_3lotXZKuqK79DqEvi3Hglcxt5ZJwxuYxdYSIPCAEpenqEt985sw37OCbBKLM1bzLKJgPZZEE2meiRD12bi1vujTtr77biyxo9XGSR1EInapBA8buuGDQIzSKm8vUK6wDmErDmJz2iN8TePRU5uDdLqvl54OLWMbILyR7ZbyfI-uF3jXW_m0T_8Gqv_6_3N-RRhFM8ON3skq3lr5V_C9Bpme-R7XR0cDDB6-ezb8O9oDlwN5tM07MbI3ARqw
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9BJ7HtYXwNUTbASLyxTE3sxOljBS0da6ZptGI8RY7tsIoomdZEY_z1nN0kpROa2LO_z2f7Z9_5dwDvXTx1Qk_5jupx7eAuKZ0wtV6Ead9P-6n0U_M5OToJxjP25dw_rz-FLRpv98YkaXfq1Wc31xAamutOz8RidehD2GB4QfE6sDH4_P142FoPuGvDuuFiDhzEG179WebftawfSCuUedtHsjWUbsNmlV-Km2uRZX-dRaPHMGtGsXRB-XlYlcmh_H2L4PG-w3wCOzU4JYOlNj2FBzp_Bo-i2vz-HH4NctKwmJAiJUc4tVlhi-TlPCnUDRlZDLwgX6sfxnK1IIKcFZkmiI1JZN8jsTPk9JMzcYl5AyaT4ppETYxe8s2-1JLT4ZScCTUvUCgSAeouzEbD6cexU4ducCTz3dJxVU9wxkRCaaAlohRlAlAkLjUuWtpLJW4sTCF-wP1WUc11yIVPdd_EC9RauvQFdPIi1y-BqDBIhPZZIj1tuGxEwgKVCk8j9jDkP11wm_mLZc1rbsJrZPGKkdmINEaRxlakMe3Ch7bM5ZLV487c-41axPUKX8Qe45SHfj_E5HdtMq5NY3ARuS4qkwfRHMXTJOwCX1OntlXD7r2eks8vLMs3DwxvEevCQaMnq8bv6utBq5z_MbRX96v9LWyOp9EknhydHO_Blme01Lr27EOnvKr0awRoZfKmXo9_ACxULL8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZgSGM8IH6KwgAj8cas1bETp48VW7VBO1VjFXuLHNuBSpFTranG_nvu3CRdEZrg2Y7t5O7sL7677wj5yOHUSSMbM9tXjsEuaVhahCjCYhAXg8LEBSYnT86Sk5n8chlf3sriD9HurUtyndOALE2-PlzY4nCT-MaR3BB_ffpYl5WJ--SBRKIE0OhZNOz8CIqHAm9g1gkD5BE1aTN_H2P7aNrgzT-jJTuX6SPycOUX-uZal-WtU2n0hDxu4CQdruX_lNxz_hnZnTQO8-fk19DTlneEVgU9BWGUVXjE1_O8sjd0FFDrkn5b_UBf05Jqel6VjgKapZNwgwiroNMjNuYUb23puLqmk7aqLv0e7lbp9PiCnms7r2DxBiDlCzIbHV98PmFNsQVmZMxrxm1fKyl1LkTiDOAKiyUjci4wqMpFhYGtQFo48WGHtMIplyodCzfACn_OGS5ekh1fefeKUJsmuXaxzE3kkH1G5zKxhY4coAWk6-kR3n7nzDRM5FgQo8w2HMoomwxkkwXZZKJHPnXPLNY8HHf23m_FlzU2ucwiqYRK40EKzR-6ZrAmdJFo76oV9gH8JWD_T3tEbYm9mxX5uLdb_Pxn4OVWCTINyR45aBVkM_ldaz3olOgfXu31_43-nuxOj0bZ-PTs6xuyF6G2h1icfbJTX63cW0BUdf4uGM1vBEUUEw
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTuLjgc8hCgMZiTeWronz1ccKVg20TlVZxXiKHNuBisypaKIx_nrunI_SPUzs2Y4c5-58v_jufgfwzkWvE3sqcNQw0g6ektKJM5tFmI2CbJTJIKPi5OlpeLzwP58H5zvgtrUwNmlfpsuByS8GZvnD5lauLuRhmyd2GIXE5-Lfgd0wQPjdg93F6Wz8reZFDR3EFzbCGYdD0gCvKZSpy-VcokSkH6YhdXN1-LYz2iDM6_mRXZD0AdyrzEpcXYo8_8cPTR7BvN1BnX7yc1CV6UD-uUbueKstPoaHDSpl43roCexo8xTuTpu4-zP4PTaspS9hRcY-oUzzwj5iymVaqCs2seB3zb5U3ylktWaCzYtcMwTFbGovInFrbPbROXEZXf6yk-KSTdvmvOyrvaJls6MzNhdqWeAXkYhM92AxOTr7cOw0PRsc6Qdu6bhqKCLfFynnoZYITxR1nkhdTrlZ2ssknii-QuCAB63iOtJxJAKuR9QoUGvp8ufQM4XRL4CpOEyFDvxUeppIbETqhyoTnkbQQaw_fXBb4SWyITSnvhp5sqFiJoEnKPDECjzhfXjfPbOq6TxunL3f6kTSmPY68fyIR3EwinH4bTeMRkmRFmF0UdEchHEc3Ujch2hLl7pVidZ7ewRVwdJ7N9Lvw0GrdZvFb3rXg04z_2NrL283_RXc98hubB7PPvTKX5V-jWisTN809vcX0M4tPw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+Analysis+of+Isoclonal+Antibody+Formats+Suggests+a+Role+for+Measuring+PD-L1+with+Low+Molecular+Weight+PET+Radiotracers&rft.jtitle=Molecular+imaging+and+biology&rft.au=Wei%2C+Junnian&rft.au=Wang%2C+Yung-Hua&rft.au=Lee%2C+Chia+Yin&rft.au=Truillet%2C+Charles&rft.date=2020-12-01&rft.issn=1860-2002&rft.eissn=1860-2002&rft.volume=22&rft.issue=6&rft.spage=1553&rft_id=info:doi/10.1007%2Fs11307-020-01527-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1536-1632&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1536-1632&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1536-1632&client=summon